For the latter, the additional impairment following the change in assumptions is disclosed below:
| not-included | Additional impairment loss |
|---|---|
| (in millions of euros) | Latin America |
| Discount rate sensitivity | not-included |
| 1% increase in discount rate | (14) |
| Long‑term growth sensitivity | not-included |
| 0.5% decrease in LT growth rate | (4) |
| Operating margin sensitivity in terminal value | not-included |
| 0.5% decrease in margin | (5) |
As part of the program to optimize premises, aiming to consolidate the agencies on one or more sites in the main countries, it was necessary to empty leased space in order to make better use of the existing space at other sites. Consequently, right‑of‑use assets concerning the empty spaces were subject to total or partial impairment loss, and likewise concerning the fixtures in these spaces.
Impairment losses of euro 147 million were recognized (euro 110 million net of tax), including euro 47 million for right‑of‑use assets, euro 39 million for sub‑leasing receivables and euro 9 million for fixtures. Accrued expenses such as facility management expenses and any taxes on vacant properties in the amount of euro 52 million are included in provisions for real estate commitments.
In 2022, euro 81 million in impairment losses had been recognized (euro 61 million net of tax), including euro 45 million for right‑of‑use assets and euro 12 million for fixtures. Accrued expenses such as lease expenses and any taxes on vacant properties in the amount of euro 24 million were included in provisions for real estate commitments.
This covers non‑recurring income and expenses. This line item mainly includes gains and losses on the disposal of assets.
| (in millions of euros) | 2023 | 2022 |
|---|---|---|
| Capital gains (losses) on disposal of assets | Capital gains (losses) on disposal of assets 2023 (206) |
Capital gains (losses) on disposal of assets 2022 2 |
| Non‑current income and (expenses) | Non‑current income and (expenses) 2023 4 |
Non‑current income and (expenses) 2022 (105) |
| Total non‑current income and (expenses) | Total non‑current income and (expenses) 2023 (202) |
Total non‑current income and (expenses) 2022 (103) |
In 2023, other non‑current income and expenses correspond mainly to the cost of the settlement reached between the attorneys general of the 50 US States, the District of Columbia and certain US territories concerning the work carried out by the former advertising agency, Rosetta (merged with Publicis Health LLC), on behalf of opioid manufacturers. Under this settlement, the expense of euro 203 million/dollar 220 million breaks down as follows: dollar (343)million to the States, dollar (7) million to costs of the attorneys general investigation and other ancillary costs, offset by an insurance reimbursement of dollar 130 million/euro 120 million (see also Note 22).
In 2022, asset disposals mainly related to the disposal of operations in Russia (see Note 2) giving rise to a loss of euro 87 million and the disposal of Qorvis LLC activities generating a loss of euro 29 million. Furthermore, the disposal of a stake held by the Group in a building located in Chicago, in the United States, generated a gain of euro 11 million.
